...
首页> 外文期刊>European journal of human genetics: EJHG >Investigations of a CA repeat in the oestrogen receptor beta gene in patients with Alzheimer's disease.
【24h】

Investigations of a CA repeat in the oestrogen receptor beta gene in patients with Alzheimer's disease.

机译:阿尔茨海默氏病患者雌激素受体β基因中CA重复的研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Several studies have shown that oestrogen treatment after menopause decreases the risk for Alzheimer's disease (AD). It is also known that oestrogen stimulates the outgrowth of nerve cells and that apolipoprotein E (Apo E) synthesis and amyloid precursor protein (APP) metabolism are regulated by oestrogen. Recently a new oestrogen receptor was identified, oestrogen receptor beta (ERbeta), located at chromosome 14q22-24. Several genes close to this chromosomal region have been implicated in AD, but the results are conflicting. Our hypothesis was that variations in the ERbeta gene could be the underlying cause to the positive findings in these genes and we have therefore investigated a CA repeat(1) in intron 5 of the ERbeta gene. Three hundred and thirty-six AD cases and 110 healthy age-matched controls were included in this study. Fourteen different alleles were found with frequencies between 0.1 and 37%. There was no significant difference between AD cases and controls when all alleles were compared. However, allele 5 was seen in 13.6% of the controls but only in 8.0% of AD cases (P=0.014; odds ratio (OR)=0.55). No AD patient homozygous for this allele was seen but three controls were homozygous. In conclusion, our findings suggest the ERbeta allele 5 to be a protective factor. However, this has to be confirmed in a larger population.
机译:几项研究表明,绝经后的雌激素治疗可降低罹患阿尔茨海默氏病(AD)的风险。还已知雌激素刺激神经细胞的生长,并且载脂蛋白E(Apo E)的合成和淀粉样前体蛋白(APP)的代谢受雌激素的调节。最近,发现了一种新的雌激素受体,雌激素受体β(ERbeta),位于染色体14q22-24处。接近这个染色体区域的几个基因已经牵涉到AD,但是结果是矛盾的。我们的假设是ERbeta基因的变异可能是这些基因中阳性结果的根本原因,因此我们研究了ERbeta基因内含子5中的CA repeat(1)。这项研究纳入了336例AD患者和110例年龄匹配的健康对照者。发现了十四个不同的等位基因,频率在0.1%到37%之间。比较所有等位基因时,AD病例与对照组之间无显着差异。但是,在对照组的13.6%中观察到等位基因5,而在AD病例中仅见8.0%(P = 0.014;优势比(OR)= 0.55)。没有AD患者对该等位基因纯合,但是三个对照是纯合的。总之,我们的发现表明ERbeta等位基因5是一种保护因子。但是,这必须在更大的人群中得到证实。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号